G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)

Taiwan · Delayed Price · Currency is TWD

31.10

-0.30 (-0.96%)

Jun 18, 2026, 1:30 PM CST

-36.14% (1Y)

Market Cap	1.98B -39.2%
Revenue (ttm)	261.21M -4.6%
Net Income	117.55M -1.2%
EPS	1.84 -1.2%
Shares Out	63.72M
PE Ratio	16.86
Forward PE	n/a
Dividend	1.17 (3.75%)
Ex-Dividend Date	Jul 29, 2025

Volume	9,470
Open	31.05
Previous Close	31.40
Day's Range	31.00 - 31.10
52-Week Range	30.60 - 56.60
Beta	-0.65
Analysts	Hold
Price Target	90.63 (+191.42%)
Earnings Date	Aug 6, 2026

About G&E Herbal Biotechnology

G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan. It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants. G&E Herbal Biotechnology Co., Ltd. was fo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 43

Stock Exchange Taipei Exchange

Ticker Symbol 4911

Full Company Profile

Financial Performance

In 2025, G&E Herbal Biotechnology's revenue was 309.13 million, an increase of 24.13% compared to the previous year's 249.03 million. Earnings were 139.20 million, an increase of 36.38%.

Financial Statements